SCHEMBL23770573

SCHEMBL23770573

Cc1ccccc1-c1nc(NSc2cccc(NC3CCC3)n2)ccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 5/20 0.36
CCNK O75909 4/20 0.36
CCNE1 P24864 4/20 0.36
CDK2 P24941 4/20 0.36
CDK9 P50750 4/20 0.36
CDK12 Q9NYV4 4/20 0.36
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PIM1 P11309 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
TSHR P16473 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770706 0.97 SMN1; SMN2 (0.36) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL23770617 0.92 CYP1A2 (0.39) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL19970024 0.90 MAPK3 (0.38) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL19970021 0.90 MAPK3 (0.38) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL19970019 0.90 MAPK3 (0.38) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL23770790 0.89 IL1B (0.32) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL23770784 0.89 SYK (0.38) CCNT1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL19970087 0.86 CCNT1 (0.35) CCNT1CCNKCCNE1CDK2CDK9
SCHEMBL23770848 0.85 IL1B (0.33) IL1BTNF
SCHEMBL23770815 0.85 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6CLK4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed